18 Feb 2021 Phase I Clinical Trial Authorisation for AVA6000 Approved by MHRA Investors | Therapeutics
16 Feb 2021 Results of Initial Evaluation of SARS-CoV-2 Lateral Flow Antigen Test with Clinical Samples Diagnostics | Investors
23 Dec 2020 Submission of Clinical Trial Application for AVA6000 Pro-doxorubixin Investors | Therapeutics
22 Dec 2020 Interview with Alastair Smith about license agreement with Astrea Bioseparations Diagnostics | Investors